SCHEMBL14576575

SCHEMBL14576575

COCCn1c(-c2c[nH]c(-c3ccc(Cl)cc3)n2)nc2cccc(C)c21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASR P41180 4/20 0.58
▸ MAPT P10636 3/20 0.40
▸ HPGD P15428 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RIPK2 O43353 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ HSD17B10 Q99714 4/20 0.37
▸ RECQL P46063 1/20 0.37
▸ CYP1A2 P05177 3/20 0.36
▸ CYP3A4 P08684 3/20 0.36
▸ CASP1 P29466 2/20 0.36
▸ CASP7 P55210 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554431 0.85 HPGD (0.57) CASRMAPTHPGDALDH1A1KDM4E
SCHEMBL14575950 0.80 RIPK2 (0.49) CASRHPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL14575975 0.80 RIPK2 (0.43) CASRMAPTHPGDALDH1A1KDM4E
SCHEMBL2554274 0.79 RIPK2 (0.45) CASRMAPTHPGDALDH1A1KDM4E
SCHEMBL14576869 0.78 KDM4E (0.49) CASRMAPTHPGDALDH1A1KDM4E
SCHEMBL2552224 0.76 CASR (0.41) CASRHPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL14616759 0.76 HPGD (0.69) CASRMAPTHPGDALDH1A1KDM4E
SCHEMBL14576556 0.76 CNR2 (0.50) CASRHPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL2551496 0.75 PTGER4 (0.54) RIPK2
SCHEMBL12284274 0.75 RIPK2 (0.57) RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 CASR 2479/4885MAPT 2704/4885HPGD 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback